Morgan Stanley analyst Steve Beuchaw upgraded Myriad Genetics to Equal Weight from Underweight based on share price underperformance and improving cancer testing survey share trends. In a research note to investors, the analyst, who has a $33 price target on the shares, said risk/reward is now balanced, given margin trends and reimbursement, upside for new products, while hereditary pricing remains a key downside risk. He added that his fundamental concerns on Myriad , including persisting price pressure in the core hereditary cancer testing franchise, and the expectation that new tests for use in prostate cancer, depression and arthritis will increase at measured paces, are "substantially unchanged."